Vulvar Cancer Market Research Report: Information by Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Biologic Therapy), End User (Hospitals & Clinics, Research & Academic Institutes, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027
ID: MRFR/MED/0914-HCR | February 2021 | Region: Global | 85 Pages
Table of Contents
REPORT PROLOGUE
MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
GLOBAL VULVAR CANCER MARKET, BY CANCER TYPE
6.1. Overview
6.2. Vulvar Squamous Cell Carcinoma
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Vulvar Melanoma
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Adenocarcinoma
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Basal Cell Carcinoma
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
GLOBAL VULVAR CANCER MARKET, BY TREATMENT TYPE
7.1. Overview
7.2. Chemotherapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Surgery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.1. Laser Surgery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.2. Excision
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.3. Skinning Vulvectomy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.4. Radical Vulvectomy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Radiation Therapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Biologic Therapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
GLOBAL VULVAR CANCER MARKET, BY END USER
8.1. Overview
8.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Research and Academic Institutes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
GLOBAL VULVAR CANCER MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Vulvar Cancer Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Vulvar Cancer Market
10.7. Key Developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
COMPANY PROFILES
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Celgene Corporation
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Merck & Co., Inc.
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Pfizer Inc.
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. GlaxoSmithKline plc
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Sanofi
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Johnson & Johnson Services, Inc.
11.11.1. Company Overview
11.11.2. Product Overview
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Others
APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL VULVAR CANCER MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL VULVAR CANCER MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL VULVAR CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10 US: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 11 US: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 12 US: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 13 CANADA: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 14 CANADA: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 15 CANADA: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 LATIN AMERICA: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 17 LATIN AMERICA: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 18 LATIN AMERICA: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 19 EUROPE: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 21 EUROPE: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: VULVAR CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: VULVAR CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: VULVAR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL VULVAR CANCER MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL VULVAR CANCER MARKET
FIGURE 4 GLOBAL VULVAR CANCER MARKET SHARE, BY CANCER TYPE, 2020 (%)
FIGURE 5 GLOBAL VULVAR CANCER MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
FIGURE 6 GLOBAL VULVAR CANCER MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL VULVAR CANCER MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: VULVAR CANCER MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: VULVAR CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: VULVAR CANCER MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: VULVAR CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: VULVAR CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: VULVAR CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL VULVAR CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 AMGEN INC..: KEY FINANCIALS
FIGURE 15 AMGEN INC.: SEGMENTAL REVENUE
FIGURE 16 AMGEN INC.: REGIONAL REVENUE
FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 18 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 19 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE
FIGURE 20 CELGENE CORPORATION: KEY FINANCIALS
FIGURE 21 CELGENE CORPORATION: SEGMENTAL REVENUE
FIGURE 22 CELGENE CORPORATION: REGIONAL REVENUE
FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 26 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS
FIGURE 27 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
FIGURE 28 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE
FIGURE 29 MERCK & CO., INC.: KEY FINANCIALS
FIGURE 30 MERCK & CO., INC.: SEGMENTAL REVENUE
FIGURE 31 MERCK & CO., INC.: REGIONAL REVENUE
FIGURE 32 NOVARTIS AG: KEY FINANCIALS
FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 34 NOVARTIS AG: REGIONAL REVENUE
FIGURE 35 PFIZER INC.: KEY FINANCIALS
FIGURE 36 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 37 PFIZER INC.: REGIONAL REVENUE
FIGURE 38 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 39 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 40 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 41 SANOFI: KEY FINANCIALS
FIGURE 42 SANOFI: SEGMENTAL REVENUE
FIGURE 43 SANOFI: REGIONAL REVENUE
FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE
FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE
Speak to Analyst
Request a Free Sample
Vulvar Cancer Market Overview
The vulvar cancer market size was valued USD 681.85 Million in 2018 and expected to grow at a 6.2% CAGR by 2025. Vulvar cancer develops on the outer skin of the female genitalia and appears as a lump or sore on the vulva, causing itching. Vulvar cancer is a rare form of cancer that develops in the tissues of the vulva. It mostly affects the exterior genital organs that safeguard a woman's reproductive system. Vulvar cervical dysplasia and human papillomavirus infection are the main causes of vulvar cancer. Painful sexual intercourse, bleeding, burning, painful urination, persistent itching, rawness and sensitivity, thicker skin, ulceration, and dark coloring in cases of melanoma are all indications of vulvar cancer.
Primary vulvar cancer occurs when cancer begins in the vulva; secondary vulvar cancer occurs when cancer spreads to other parts of the body. Squamous cell carcinoma, vulvar melanoma, adenocarcinoma, sarcoma, and verrucous carcinoma are the five kinds of vulvar cancer. The type and stage of vulvar cancer, as well as any side effects, the patient's preferences, and overall health, all influence vulvar cancer treatment.
Many sexual partners, vulvar intraepithelial neoplasia (VIN), HPV infection, genital warts, smoking, and vulvar intraepithelial neoplasia are all risk factors. Squamous cell tumors account for the majority of vulvar malignancies. Adenocarcinoma, melanoma, sarcoma, and basal cell carcinoma are some of the other forms. Physical examination leads to a suspicion of cancer, which is then verified by tissue biopsy. Screening regularly is not advised.
The HPV vaccine is one option for prevention. Surgery, radiation therapy, chemotherapy, and biologic therapy are all common therapies. In 2018, vulvar cancer struck 44,200 persons worldwide, resulting in 15,200 fatalities. After the age of 45, the symptoms usually appear.
COVID-19 Analysis
The outbreak of the COVID-19 pandemic has had a substantial influence on virtually every business in the world. Furthermore, lockdown enforcement and restrictions on the passage of non-essential commodities and resources in numerous countries have disrupted the supply chain for electronic components and networking equipment. As a result, the delivery of medical equipment has been delayed. The COVID-19 epidemic has wreaked havoc on healthcare systems around the world, as well as the Vulvar Cancer Market Growth. Cancer screening and other health prevention services, as well as elective surgeries, should be postponed unless the risks outweighed the benefits, according to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations, to secure the hospital infrastructure for the treatment of COVID-19 patients. As a result, the COVID-19 pandemic has influenced ongoing clinical trials. The situation, though, is likely to progressively improve and also improve Market Analysis during the forecast period.
Vulvar Cancer Market Dynamics
Drivers
The increasing prevalence of Vulvar Cancer Market Outlook, rising investment in research & development activities, and growing government initiatives to raise public awareness about vulvar cancers are the primary drivers driving the global Market Size. Cancer is the second-leading cause of death globally, according to the World Health Organization (WHO), with over 18.1 million cases identified during the historic forecast period. According to the WHO, roughly 19 million new cancer cases will be diagnosed worldwide. Vulvar cancer affects roughly 6% of female reproductive organ cancers and 0.7% of all cancers in women in the United States. According to the American Cancer Society, approximately 6,120 new cases of vulvar cancer will be detected in the United States during the forecast period. During the projection period, this figure will boost the Vulvar Cancer Market Growth.
Restraints
The most common therapy for vulvar cancer is surgery. Formation of fluid-filled cysts near surgical sites, blood clots that may go to the lungs, urinary infections, decreased sexual desire, and lymphedema is some of the problems and side effects of vulvar and groin node surgery. Nausea and vomiting, hair loss, mouth or vaginal sores, changes in the menstrual cycle, premature menopause, and infertility are all common adverse effects of some of the medications used to treat vulvar cancer. Diarrhea is another common side effect. However, the treatment's negative effects are projected to stifle commercial growth. It also affects the bone marrow's blood-forming cells, resulting in low blood counts. One of the primary reasons limiting Vulvar Cancer Market Trends is this.
Vulvar cancer market research includes the Analysis for each country's growth in healthcare capital expenditure, installed base of various types of products for the digital health technologies market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios, as well as their impact on the Vulvar Cancer Market Size. The global vulvar cancer treatment market is likely to be driven by technical advancements, treatment treatments, and diagnosis, as well as increased investment in medication discovery, which raises the odds of vulvar cancer being successfully treated. In the forecast period, the Vulvar Cancer Market Share is expected to be driven by the rising incidence of vulvar cancer in women.
Vulvar Cancer Market Segment Overview
The study depicts the Vulvar Cancer Market's segmentation by cancer type, treatment type, end-users, and geography.
Based on the cancer type, the market has been segmented as follows:
- Vulvar Squamous Cell Carcinoma
- Vulvar Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
Based on the treatment type, the market has been segmented as follows:
- Chemotherapy
- Surgery
- Laser Surgery
- Excision
- Skinning Vulvectomy
- Radical Vulvectomy
- Radiation Therapy
- Biologic Therapy
Based on the end-user, the market has been segmented as follows:
- Hospitals & Clinics
- Research & Academic Institutes
- Others
Based on the region, the market has been segmented as follows:
The Americas
- North America
- US
- Canada
- Latin America
Europe
- Western Europe
- France
- Germany
- Spain
- UK
- Italy
- The Rest of Western Europe
- Eastern Europe
Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- The Rest of Asia-Pacific
The Middle East & Africa
- The Middle East
- Africa
Vulvar Cancer Market Regional Classification
Due to the increased prevalence of vulvar cancer, The Americas are likely to lead the vulvar cancer market.
Due to the presence of significant market participants such as F.Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, and Sanofi, Europe is likely to hold the second-largest proportion of the market.
Because of rising cancer awareness and increased R&D in the field of oncology, Asia-Pacific is predicted to be the fastest-growing regional market.
Due to the high incidence rate of vulvar cancer in the Middle East and Africa, the vulvar cancer market is predicted to develop steadily throughout the forecast period.
Vulvar Cancer Market Competitive Landscape
The major key players of the global vulvar cancer market are Amgen Inc. (US), GlaxoSmithKline plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (the US), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), and Johnson & Johnson Services, Inc. (the US). Product launches, acquisitions, and partnerships are among the leading players' growth tactics, all of which are contributing to the market's global expansion.
Recent Developments
Novartis, a Swiss-based corporation, introduced Oncofocus, the world's most precise oncology test for detecting the kind of cancer, increasing the likelihood of effective therapy.
On January 1, 1891, George Merck, at 23 years old, established Merck & Co in the United States to distribute excellent chemicals across New York City and the surrounding areas. In the pursuit of their purpose to save and improve lives, they have been creating for life, bringing forth medicines and vaccines for many of the world's most difficult diseases.
With 74,000 workers and USD 13.6 billion in research and development, Merck & Co. shows their dedication to patients and public health by expanding access to health care through far-reaching policies, programs, and collaborations.
Report Overview
It also analyses trends and co-development arrangements to find business opportunities in the Vulvar Cancer Market. Product mapping is available for all major market participants' important products. It also aids firms in complying with current health and safety laws. The study breaks down the industry into several sectors and delivers the most accurate revenue estimates for the overall market across various geographies. In this research analysis, the global market potential, industry dynamics, and leading vendors operating in the market are all covered in depth.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | USD 681.85 Million (2018) |
| CAGR | 6.2% (2019-2025) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Information by Cancer Type, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), and Johnson & Johnson Services, Inc. (US) |
| Key Market Opportunities |
|
| Key Market Drivers | The vulvar cancer market in the Middle East & Africa is expected to steadily grow during the forecast period owing to the high incidence rate of vulvar cancer. |
